Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Musharraf, Syed Ghulam ^a   Mazhar, Shumaila ^a   Choudhary, Muhammad Iqbal ^a,b   Rizi, Nadeem ^c   Atta Ur Rahman, ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c JINNAH POSTGRADUATE MEDICAL CENTRE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BILE ACID; G PROTEIN COUPLED RECEPTOR; KETONE BODY; PYRUVIC ACID;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CITRIC ACID CYCLE; CLUSTER ANALYSIS; FEMALE; HUMAN; LUNG TUMOR; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; METABOLOME; METABOLOMICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SMOKING; YOUNG ADULT;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; CASE-CONTROL STUDIES; CITRIC ACID CYCLE; CLUSTER ANALYSIS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KETONE BODIES; LUNG NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRUVIC ACID; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SMOKING; YOUNG ADULT;

EID: 84923642510     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08607     Document Type: Article

References (39)

1. Ganti, A. K. & Mulshine, J. L. Lung Cancer Screening. The oncologist 11, 481-487, doi:10.1634/theoncologist.11-5-481 (2006).
2. Wardwell, N. R. & Massion, P. P. Novel strategies for the early detection and prevention of lung cancer. Seminars in oncology 32, 259-268 (2005).
3. Ferlay, J. S. I. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research onCancer (2013). Available at: http://globocan.iarc.fr/Pages/fact-sheets-population.aspx. (Accessed:12 June 2014).
4. Hassanein, M. et al. The state of molecular biomarkers for the early detection of lung cancer. Cancer prevention research (Philadelphia, Pa.) 5, 992-1006, doi:10.1158/1940-6207.capr-11-0441 (2012).
5. Ramirez, J. L. et al.Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer letters 193, 207-216 (2003).
6. Musharraf, S. G. et al. Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 17, 223-230, doi:10.3109/1354750x.2012.657245 (2012).
7. Hori, S. et al. A metabolomic approach to lung cancer. Lung Cancer 74, 284-292 (2011).
8. Yang, J. et al.High Performance Liquid Chromatography - Mass Spectrometry for Metabonomics: Potential Biomarkers for Acute Deterioration of Liver Function in Chronic Hepatitis B. Journal of Proteome Research 5, 554-561, doi:10.1021/pr050364w (2006).
9. Kami, K. et al. Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 9, 444-453, doi:10.1007/s11306-012-0452-2 (2013).
10. Rocha, C. M. et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 10, 4314-4324, doi:10.1021/pr200550p (2011).
11. Carrola, J. et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 10, 221-230, doi:10.1021/pr100899x (2011).
12. Jordan, K. W. et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 68, 44-50, doi:10.1016/j.lungcan.2009.05.012 (2010).
13. Baeten, K., Adriaensens, P. & Stinissen, P. inventors. Metabolic markers for diagnosing of cancer patent. World Intellectual Property Organization patent WO 2011128256 A1. 2011 Oct 20.
14. Maeda, J. et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10, 690 (2010).
15. Dong, J. et al. Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 6, 478-488, doi:DOI 10.1007/s11306-010-0215-x (2010).
16. Guo, Y. et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clinica chimica acta; international journal of clinical chemistry 414, 135-141, doi:10.1016/j.cca.2012.08.010 (2012).
17. Fan, T. et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13) C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8, 41-59 (2009).
18. Xue, R. et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry 22, 3061-3068 (2008).
19. Elizabeth, J., Nordström, A., Morita, H. & Siuzdak, G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res. 6, 459-468 (2007).
20. Niu, Y. et al. Preliminary results of metabolite in serum and urine of lung cancer patients detected by metabolomics. Zhongguo fei ai za zhi = Chinese journal of lung cancer 15, 195-201, doi:10.3779/j.issn.1009-3419.2012.04.01 (2012).
21. Phillips, M. et al.Detection of lung cancer using weighted digital analysis of breath biomarkers. Clinica Chimica Acta 393, 76-84 (2008).
22. Poli, D. et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878, 2643-2651, doi:10.1016/j.jchromb.2010.01.022 (2010).
23. Song, G. et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 67, 227-231 (2010).
24. Kischkel, S. et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects - confounding variables, influence of normalization and statistical algorithms. Clinica Chimica Acta 411, 1637-1644 (2010).
25. O'Neill, H. J., Gordon, S. M., O'Neill, M. H., Gibbons, R. D. & Szidon, J. P. A computerized classification technique for screening for the presence of breath biomarkers in lung cancer. Clinical chemistry 34, 1613-1618 (1988).
26. Musharraf, S. G., Mazhar, S., Siddiqui, A. J., Choudhary, M. I. & Atta ur, R. Metabolite profiling of human plasma by different extraction methods through gas chromatography-mass spectrometry-an objective comparison. Anal Chim Acta 804, 180-189, doi:10.1016/j.aca.2013.10.025 (2013).
27. Catovsky, D. et al. A classification of acute leukaemia for the 1990s. Annals of hematology 62, 16-21 (1991).
28. Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66, 5977-5980, doi:10.1158/0008-5472.can-05-4673 (2006).
29. Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews Cancer 7, 763-777, doi:10.1038/nrc2222 (2007).
30. Menendez, J. A. et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 101, 10715-10720, doi:10.1073/pnas.0403390101 (2004).
31. Zhou, W. et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67, 2964-2971, doi:10.1158/0008-5472.can-06-3439 (2007).
32. Krycer, J. R., Sharpe, L. J., Luu, W. & Brown, A. J. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends in endocrinology and metabolism: TEM 21, 268-276, doi:10.1016/j.tem.2010.01.001 (2010).
33. Yang, Y. A., Han, W. F., Morin, P. J., Chrest, F. J. & Pizer, E. S. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Experimental cell research 279, 80-90 (2002).
34. Heasley, L. E. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20, 1563-1569, doi:10.1038/sj.onc.1204183 (2001).
35. Rozengurt, E. Neuropeptides as growth factors for normal and cancerous cells. Trends in endocrinology and metabolism: TEM 13, 128-134 (2002).
36. Naughton, S. S., Mathai, M. L., Hryciw, D. H. & McAinch, A. J. Fatty Acid modulation of the endocannabinoid system and the effect on food intake and metabolism. International journal of endocrinology 2013, 361895, doi:10.1155/2013/361895 (2013).
37. Wu, C. P., Calcagno, A. M. & Ambudkar, S. V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Current molecular pharmacology 1, 93-105 (2008).
38. St-Pierre, M. V., Kullak-Ublick, G. A., Hagenbuch, B. & Meier, P. J. Transport of bile acids in hepatic and non-hepatic tissues. The Journal of experimental biology 204, 1673-1686 (2001).
39. Gatenby, R. A. & Gillies, R. J. A microenvironmental model of carcinogenesis. Nature reviews Cancer 8, 56-61, doi:10.1038/nrc2255 (2008).